Exploring the efficacy of interferon nebulization combined with immunoglobulin in the treatment of adenovirus pneumonia in children

Background: This study explores the efficacy of interferon nebulization combined with immunoglobulin in treating adenovirus pneumonia in children. Methods: Based on existing case records, a retrospective analysis was conducted on the clinical data of 100 pediatric patients with adenovirus pneumonia treated in our hospital from August 2020 to August 2023. According to the recorded different treatment methods, this study included 50 cases in the observation group (receiving interferon nebulization combined with immunoglobulin treatment) and 50 cases in the control group (receiving interferon nebulization treatment). Comparing the effects of the two treatment methods on the children’s efficacy. Results: The total effective rate in the observation group was significantly higher than that in the control group, with a lower inefficacy rate (χ2 = 5.263, p = 0.022 < 0.05). After treatment, the clinical indicators in the observation group, including the disappearance times of cough, fever, sputum production, and lung rales, were shorter than those in the control group (t = 16.159, p < 0.001; t = 23.804, p < 0.001; t = 17.247, p < 0.001; t = 28.159, p < 0.001). Before treatment, there was no significant difference in the levels of inflammatory factors (White Blood Cell (WBC), C-Reactive Protein (CRP)) between the observation and the control groups (t > 0.05); seven days after treatment, the levels of WBC and CRP in the observation group were lower than the control group (t = 12.082, p < 0.001; t = 8.828, p < 0.001). The incidence of complications in the observation group was lower than in the control group (χ2 = 4.000, p = 0.046 < 0.05). Conclusions: Interferon nebulization combined with immunoglobulin demonstrates significant clinical efficacy in children with adenovirus pneumonia, rapidly alleviating clinical symptoms, reducing inflammatory response, improving immune function, and ensuring high safety, worth of promoting in clinical practice.

Interferon; Immunoglobulin; Children’s adenovirus pneumonia; Efficacy; Inflammatory factors

[1] Tian J, Wang X, Li Q, Zhang L, Ai J, Feng G, et al. Clinical epidemiology of adenovirus pneumonia among Chinese hospitalized children. Archives of Microbiology. 2024; 206: 135.

[2] Li M, Han XH, Liu LY, Yao HS, Yi LL. Epidemiological characteristics, clinical characteristics, and prognostic factors of children with atopy hospitalised with adenovirus pneumonia. BMC Infectious Diseases. 2021; 21: 1051.

[3] Jiang J, Sun L, Huang M. Abnormal changes in IL-13 and IL-17A serum levels in children with adenovirus pneumonia and their diagnostic value. Iranian Journal of Immunology. 2024; 21: 81–88.

[4] Lin L, Tang M, Li D, Fei H, Zhang H. Combined intravenous ribavirin and recombinant human interferon α1b aerosol inhalation for adenovirus pneumonia with plastic bronchitis in children: a case report and review of literature. Frontiers in Pediatrics. 2024; 12: 1295133.

[5] Wang N, Fang Y, Dong H, Wang L, Hou M, Wang W, et al. Clinical features and prediction of risk factors for severe adenovirus pneumonia in children. Translational Pediatrics. 2024; 13: 63–71.

[6] Almontasheri A, Al-Husayni F, Alsuraihi AK, Binyahib H, Albanna AS. The clinical course of COVID-19 pneumonia in a 19-year-old man on intravenous immunoglobulin replacement therapy for X-linked agammaglobulinemia. American Journal of Case Reports. 2021; 22: e929447.

[7] Harada N, Sonoda M, Ishimura M, Eguchi K, Kinoshita K, Matsuoka W, et al. Pretransplant ribavirin and interferon-α therapy for rhinovirus interstitial pneumonia in a RAG1-deficient infant. Journal of Infection and Chemotherapy. 2024; 30: 362–365.

[8] Subspecialty Group of Respiratory, the Society of Pediatrics, Chinese Medical Association; Editorial Board, Chinese Journal of Pediatrics; China Medicine Education Association Committee on Pediatrics. Guidelines for the management of community-acquired pneumonia in children (2024 revision). Chinese Journal of Pediatrics. 2024; 62: 920–930. (In Chinese)

[9] Shen YY, Feng ZQ, Wang ZP, Wang XQ, Luo C, Liu QZ. Efficacy of azithromycin combined with intravenous immunoglobulin in the treatment of refractory mycoplasma pneumoniae pneumonia in children: a meta-analysis. BMC Pediatrics. 2024; 24: 678.

[10] Li ZZ, Xie LL, Wang H, Wang SG, Wu JG. Clinical observation of reduning combined with recombinant human interferon α-2b in the treatment of children with viral pneumonia. Evidence-Based Complementary and Alternative Medicine. 2022; 2022: 1739561.

[11] Lin ZL, Xu X, Yang JJ, Lu LQ, Huang H, Hua XZ, et al. Efficacy of budesonide/formoterol inhalation powder in treating viral pneumonia in children. World Journal of Clinical Cases. 2024; 12: 4469–4475.

[12] Yu X, Ma Y, Gao Y, You H. Epidemiology of adenovirus pneumonia and risk factors for bronchiolitis obliterans in children during an outbreak in Jilin, China. Frontiers in Pediatrics. 2021; 9: 722885.

[13] Rajbanshi A, Giri P, Laha S, Poddar S. Epidemiology, clinical presentation, and respiratory sequelae of severe adenoviral pneumonia in children admitted in a tertiary care pediatric intensive care unit from Eastern India: a single-center observational study. Journal of Pediatric Critical Care. 2022; 9: 131–138.

[14] Cai JY, Yan CY, Wang XQ, Luo ZX, Luo J, Li QB, et al. Clinical characteristics and risk factors for bronchoscopic airway mucus hypersecretion in childhood pneumonia infected by different pathogens. Chinese Journal of Pediatrics. 2023; 61: 719–725. (In Chinese)

[15] Jain H, Singh G, Bhuta K, Thapa SS, Sah BP. Successful treatment of severe adenovirus pneumonia with cidofovir in a immunocompetent patient. Chest. 2022; 162: A315.

[16] Cai S, Zhu CH, Chen FG, Liu F, Gao ML, Xiong Y. Establishment of a risk model for severe adenovirus pneumonia and prospective study of the timing of intravenous immunoglobulin therapy in children. Chinese Journal of Contemporary Pediatrics. 2023; 25: 619–625. (In Chinese)

[17] Zeng QL, Chen RY, Lv XY, Huang S, Li WZ, Pan YJ, et al. Functional cure induced by tenofovir alafenamide plus peginterferon-alpha-2b in young children with chronic hepatitis B: a case series study. BMC Infectious Diseases. 2024; 24: 830.

[18] Chen L, Wu Y, Sun Y, Qiao S, Xiao B, Wang J, et al. Combined therapy of local recombinant human interferon α1b injection and acupuncture on verruca vulgaris: a retrospective study. Archives of Dermatological Research. 2023; 315: 2365–2373.

[19] Luo J, Yang M, Zeng L, Pan X, Liu D, Diao S, et al. Safety and effectiveness of inhaling different dosage recombinant human interferon α1b for bronchiolitis in children: a systematic review and meta-analysis. Evidence-Based Complementary and Alternative Medicine. 2022; 2022: 2229735.

[20] Yin P, Meng J, Chen J, Gao J, Wang D, Liu S, et al. Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study. Virology Journal. 2021; 18: 142.

[21] Yang L, Zhang G, Huang L, Ren X, Su Y, Wang C, et al. The effect of recombinant human interferon α1b treatment of infants hospitalized with lower respiratory tract infection on subsequent wheezing. Jornal de Pediatria. 2021; 97: 617–622.

[22] Roquilly A, Francois B, Huet O, Launey Y, Lasocki S, Weiss E, et al.; Atlanrea study group and the Société Française d’Anesthésie Réanimation (SFAR) Research Network. Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial. Intensive Care Medicine. 2023; 49: 530–544.

[23] Ramachandram DS, Kow CS, Hasan SS, Thiruchelvam K. Effect of intravenous immunoglobulin on mortality in hospitalized patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Health Science Reports. 2024; 7: e2239.

[24] Li Y, Chen B. Gamma globulin combined with acyclovir for children with infectious mononucleosis and their effect on immune function. American Journal of Translational Research. 2023; 15: 4399–4407.

[25] Hu T, Liu CH, Lei M, Zeng Q, Li L, Tang H, et al. Metabolic regulation of the immune system in health and diseases: mechanisms and interventions. Signal Transduction and Targeted Therapy. 2024; 9: 268.

[26] Abdolahi N, Kaheh E, Golsha R, Khodabakhshi B, Norouzi A, Khandashpoor M, et al. Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020; 21: 549.

[27] Cai S, Zhu CH, Chen FG, Liu F, Gao ML, Xiong Y. Establishment of a risk model for severe adenovirus pneumonia and prospective study of the timing of intravenous immunoglobulin therapy in children. Chinese Journal of Contemporary Pediatrics. 2023; 25: 619–625. (In Chinese)

[28] Inga P, Pavel T, Tatiana D, Svetlana S, Timur S, Irina A, et al. Interferon alpha-2b treatment for exophytic nasal papillomas and human papillomavirus infection. Brazilian Journal of Otorhinolaryngology. 2024; 90: 101449.

[29] Ferri DM, Nassar C, Manion KP, Kim M, Baglaenko Y, Muñoz-Grajales C, et al. Elevated levels of interferon-α act directly on B cells to breach multiple tolerance mechanisms promoting autoantibody production. Arthritis & Rheumatology. 2023; 75: 1542–1555.

[30] Sun L, Bi J, Zhen W, Wang M, Song H. Effects of ganciclovir combined with recombinant human interferon-α on clinical efficacy and immune function in children with infectious mononucleosis. Pakistan Journal of Medical Sciences. 2024; 40: 1473–1478.

[31] Ma X, Gao W, An J. Clinical effect of reduning combined with gamma globulin treatment on symptom improvement serum levels of IL-6, 25-(OH)D and LDH in children with severe mycoplasma pneumonia. Pakistan Journal of Medical Sciences. 2022; 38: 826–832.

[32] Baek DW, Song GY, Lee HS, Do YR, Lee JH, Yhim HY, et al. Clinical efficacy of prophylactic intravenous immunoglobulin for elderly DLBCL patients with hypogammaglobulinemia in the COVID-19 pandemic era. Frontiers in Oncology. 2024; 14: 1380492.

[33] Wang XX, Han HW, Jiao FY, Zhang WH. Timing of vaccination in children after intravenous immunoglobulin therapy for Kawasaki disease. Asian Journal of Pediatric Research. 2024; 14: 57–64.

[34] Pontali E, Volpi S, Antonucci G, Castellaneta M, Buzzi D, Tricerri F, et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. Journal of Allergy and Clinical Immunology. 2020; 146: 213–215.

[35] Xu N, Xu J, Li H, Qian L, Qiao L. Analysis of curative effects of human gamma globulin on bacterial pneumonia in pediatric patients. Pakistan Journal of Pharmaceutical Sciences. 2019; 32: 2385–2390.

[36] Atosuo J, Karhuvaara O, Suominen E, Virtanen J, Vilén L, Nuutila J. The role of gamma globulin, complement component 1q, factor B, properdin, body temperature, C-reactive protein and serum amyloid alpha to the activity and the function of the human complement system and its pathways. Journal of Immunological Methods. 2024; 531: 113709.

[37] Léo JGP, Siqueira CB, Motta JOCD, Vasconcellos IF, Araujo YR, Glehn FV, et al. The use of intravenous immunoglobulin as a rescue therapy for refractory parainfectious leprosy-related neuritis: a case series. Anais Brasileiros de Dermatologia. 2024; 99: 736–739.

[38] Won J, Jo A, Gil CH, Kim S, Shin H, Jik Kim H. Inhaled delivery of recombinant interferon-lambda restores allergic inflammation after development of asthma by controlling Th2- and Th17-cell-mediated immune responses. International Immunopharmacology. 2022; 112: 109180.